Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, Bernard, Wanner, Christoph, Lachin, John M., Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa +4 more·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1504720

Cited by (12,156)

Items 1,001–1,100 of 12,156

Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
Jan Wintrich, Ingrid Kindermann, Christian Ukena, Simina‐Ramona Selejan, Christian M. Werner, Christoph Maack, Ulrich Laufs, Carsten Tschöpe, Stefan D. Anker, Carolyn S.P. Lam et al. · 2020 · Clinical Research in Cardiology
Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study
Tomoe Kinoshita, Masashi Shimoda, Koji Nakashima, Yoshiro Fushimi, Yurie Hirata, Akihito Tanabe, Fuminori Tatsumi, Hidenori Hirukawa, Junpei Sanada, Kenji Kohara et al. · 2020 · Journal of Diabetes Investigation
Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review
Jun Inaishi, Yoshifumi Saisho · 2020 · Nutrients
Chronic Kidney Disease as a Systemic Inflammatory Syndrome: Update on Mechanisms Involved and Potential Treatment
Francesca Tinti, Silvia Lai, Annalisa Noce, Silverio Rotondi, Giulia Marrone, Sandro Mazzaferro, Nicola Di Daniele, Anna Paola Mitterhofer · 2021 · Life
Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
Justin T. Parizo, Jeremy D. Goldhaber‐Fiebert, Joshua A. Salomon, Kiran K. Khush, John A. Spertus, Paul A. Heidenreich, Alexander T. Sandhu · 2021 · JAMA Cardiology
Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Qiong Wei, Xinyue Xu, Li Guo, Jia Li, Ling Li · 2021 · Frontiers in Endocrinology
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Maria Ida Maiorino, Katherine Esposito · 2021 · Cardiovascular Diabetology
Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
Raparelli, Valeria, Elharram, Malik, Moura, Cristiano S., Abrahamowicz, Michal, Bernatsky, Sasha, Behlouli, Hassan, Pilote, Louise · 2020 · Journal of the American Heart Association
Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: Reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron emission tomography. A randomized, controlled trial
Mads Vandsted Svart, Lars Christian Gormsen, Jakob Hansen, D Zeidler, Michael Gejl, Kim Vang, Joel Aanerud, Niels Møller · 2018 · PLoS ONE
Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective, single‐arm trial (LEAD trial)
Yoshio Sumida, Kenta Murotani, Miyoko Saito, Atsuko Tamasawa, Yusuke Osonoi, Masashi Yoneda, Takeshi Osonoi · 2018 · Hepatology Research
Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition
Nitin A. Das, Andrea J. Carpenter, Anthony M. Belenchia, Annayya Rao Aroor, Makoto Noda, Ulrich K. Siebenlist, Bysani Chandrasekar, Vincent Gerard DeMarco · 2019 · Cellular Signalling
Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes
Michael Fralick, Sarah K. Chen, Elisabetta Patorno, Seoyoung C. Kim · 2020 · Annals of Internal Medicine
Mortality in Patients with Diabetic Foot Ulcers: Causes, Risk Factors, and Their Association with Evolution and Severity of Ulcer
José Antonio Rubio, Sara Jiménez, José Luis Lázaro‐Martínez · 2020 · Journal of Clinical Medicine
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction
Jacob Allen Udell, W. Schuyler Jones, Mark Colquhoun Petrie, Josephine Harrington, Stefan D. Anker, Deepak L. Bhatt, Adrian F. Hernandez, Javed Butler · 2022 · Journal of the American College of Cardiology
Doxorubicin-induced cardiotoxicity and risk factors
Carl Belger, Carmelita Abrahams, A. Imamdin, S. Lecour · 2023 · International Journal of Cardiology: Heart & Vasculature
Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease
Mitsuko Inoue, Akinori Hayashi, Tomomi Taguchi, Riina Arai, Sayaka Sasaki, Koji Takano, Yusuke Inoue, Masayoshi Shichiri · 2018 · Journal of Diabetes Investigation
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension
Keith C. Ferdinand, Joseph L. Izzo, Jisoo Lee, Leslie Meng, Jyothis Thomas George, Afshin Salsali, LEO J. SEMAN · 2019 · Circulation
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Thomas A. Zelniker, Eugene Braunwald M. D · 2020 · Journal of the American College of Cardiology
Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
Andrew Peter McGovern, Michael Hogg, Beverley M. Shields, Naveed A. Sattar, Rury R. Holman, Ewan R. Pearson, Andrew Tym Hattersley, Angus G. Jones, John Dennis · 2020 · BMJ Open Diabetes Research & Care
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction
Massar Omar, Jesper Jensen, Peter Hartmund Frederiksen, Caroline Kistorp, Lars Melgaard Videbæk, Mikael Kjær Poulsen, Sören Möller, Mulham Ali, Finn Gustafsson, Lars Køber et al. · 2020 · Journal of the American College of Cardiology
Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective
Jing Cui, Yanfei Liu, Yiwen Helen Li, Fengqin Xu, Yue Liu · 2021 · Frontiers in Cardiovascular Medicine
Sodium‐glucose cotransporter‐2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation
Mi Na Kim, Joon Ho Moon, Young Min Cho · 2021 · Diabetes Obesity and Metabolism
Sodium glucose cotransporter 2 inhibition in the diabetic kidney
Aleksandra Novikov, Volker Vallon · 2015 · Current Opinion in Nephrology & Hypertension
Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials
Michaela Beatrice Rehman, Benoit Valentin Tudrej, J. Soustre, Marielle Buisson, P. Archambault, Denis Pouchain, Hélène Vaillant-Roussel, François Gueyffier, Jean‐Luc Faillie, M.-C. Pérault-Pochat et al. · 2016 · Diabetes & Metabolism
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
Bruce Charles Neal, Vlado Perkovic, Kenneth W. Mahaffey, Greg Fulcher, Ngozi Erondu, Mehul G. Desai, Wayne C. Shaw, Gordon Law, Marc K. Walton, Norm Rosenthal et al. · 2017 · Diabetes Obesity and Metabolism
Effects of glycaemic management on diabetic kidney disease
Richard J. MacIsaac, George Jerums, Elif Ilhan Ekinci · 2017 · World Journal of Diabetes
Sex and gender differences in therapy of type 2 diabetes
Alexandra Kautzky‐Willer, Jürgen Harreiter · 2017 · Diabetes Research and Clinical Practice
Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes
Milton Packer · 2017 · Diabetes Care
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
Theodosios D. Filippatos, Angelos Liontos, Ioanna Papakitsou, Moses Elisaf · 2019 · Postgraduate Medicine
Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
Qingguo Lü, Jia Liu, Xuan Li, Xiaodong Sun, Jingwen Zhang, Di Ren, Nanwei Tong, Ji Li · 2019 · Molecular and Cellular Endocrinology
Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology
Nathan D. Wong, Peter Paul Toth, Ezra A. Amsterdam · 2019 · Trends in Cardiovascular Medicine
Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus
Wei Yong Liu, Xianghai Zhou, Yufeng Li, Simin Zhang, Xiaoling Cai, Rui Zhang, Siqian Gong, Xueyao Han, Linong Ji · 2020 · Medicine
Diabetes in ageing: pathways for developing the evidence base for clinical guidance
Medha N. Munshi, Graydon S. Meneilly, Leocadio Rodríguez‐Mañas, Kelly L. Close, Paul R. Conlin, Tali Cukierman‐Yaffe, Angus Forbes, Om P. Ganda, C. Ronald Kahn, Elbert S. Huang et al. · 2020 · The Lancet Diabetes & Endocrinology
eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined
Alejandro Meraz-Muñoz, Jordan J. Weinstein, Ron Wald · 2021 · Kidney360
Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy
Yongwei Yu, Jiaqun Que, Shuai Liu, Kaiyu Huang, Qian Lu, Yingbei Weng, Fangning Rong, Lei Wang, Yingying Zhou, Yangjing Xue et al. · 2022 · Frontiers in Cardiovascular Medicine
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association · 2021 · Cardiology Discovery
Inflammasomes and Atherosclerosis: a Mixed Picture
Alan R. Tall, Karin Bornfeldt · 2023 · Circulation Research
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Xie, Yan, Bowe, Benjamin, Xian, Hong, Loux, Travis, McGill, Janet B, Al-Aly, Ziyad · 2023 · The Lancet Diabetes & Endocrinology
Systemic Aging Fuels Heart Failure: Molecular Mechanisms and Therapeutic Avenues
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li · 2024 · ESC Heart Failure
Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease
Patorno, Elisabetta, Htoo, Phyo T., Glynn, Robert J., Schneeweiss, Sebastian, Wexler, Deborah J., Pawar, Ajinkya, Bessette, Lily G., Chin, Kristyn, Everett, Brendan M., Kim, Seoyoung C. · 2021 · Annals of Internal Medicine
Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
DAVID H. FITCHETT, Jacob Allen Udell, Silvio E. Inzucchi · 2016 · European Journal of Heart Failure
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
Tushar Madaan, Mohd Akhtar, Abul Kalam Najmi · 2016 · European Journal of Pharmaceutical Sciences
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald M. D, Itamar Raz, Matthew Aaron Cavender, KyungAh Im, Ofri Mosenzon, Jacob Allen Udell, Boaz Hirshberg, Pia S. Pollack et al. · 2016 · JAMA Cardiology
The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Merlin C. Thomas · 2017 · Diabetes & Metabolism
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials
Matteo Monami, Besmir Nreu, Stefania Zannoni, Carlotta Lualdi, Edoardo Mannucci · 2017 · Diabetes Research and Clinical Practice
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Francesco Paneni, Thomas Felix Lüscher · 2017 · The American Journal of Medicine
Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment
Tian‐Hua Xu, Zitong Sheng, Li Yao · 2017 · Frontiers of Medicine
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Abdullah Kaplan, Emna Abidi, Ahmed Fawzy EL‐Yazbi, Ali Hussein Eid, George W. Booz, Fouad Anthony Zouein · 2018 · Heart Failure Reviews
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
Gert J. Mayer, Christoph Wanner, Matthew R. Weir, Silvio E. Inzucchi, Audrey Koitka‐Weber, Stefan Hantel, Maximilian von Eynatten, Bernard Zinman, David Z.I. Cherney · 2019 · Kidney International
<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
Simes, Bryce C, MacGregor, Gordon G · 2019 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Mohammed Altigani Abdalla, Harshal Deshmukh, Stephen Lawrence Atkin, Thozhukat Sathyapalan · 2020 · Therapeutic Advances in Endocrinology and Metabolism
Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018
Clemens Engler, Marco Leo, Bernhard Erich Pfeifer, Martin Juchum, Di Chen-Koenig, Karin Pölzl, Hans Schoenherr, David Vill, Juliana Oberdanner, Egon Eisendle et al. · 2020 · BMJ Open Diabetes Research & Care
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Matthew Anson, Sizheng Steven Zhao, Philip J. Austin, Gema Hernández, Rayaz Ahmed Malik, Uazman Alam · 2023 · Diabetologia
A safety update on sodium glucose co-transporter 2 inhibitors
Fitchett, David · 2019 · Diabetes, Obesity and Metabolism
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Clement Lo, Tadashi Toyama, Ying Wang, Jin Lin, Yoichiro Hirakawa, Min Jun, Alan Cass, Carmel Mary Hawley, Helen Pilmore, Sunil V. Badve et al. · 2018 · Cochrane Database of Systematic Reviews
Entwicklung und Wandel in der Gesundheitspolitik
Wille, Eberhard · 2016 · Peter Lang D eBooks
Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
Takashi Maruyama, Hiroyuki Takashima, Hidetaka Oguma, Yoshihiro Nakamura, Michiko Ohno, Kei Utsunomiya, Tetsuya Furukawa, Ritsukou Tei, Masanori Abe · 2019 · Diabetes Technology & Therapeutics
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
William T. Abraham, Mitchell A. Psotka, Mona Fiuzat, Gerasimos S Filippatos, JoAnn M. Lindenfeld, Roxana Mehran, Amrut V. Ambardekar, Peter E. Carson, Richard Jacob, James L. Januzzi et al. · 2020 · JACC Heart Failure
Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
Changzhen Ren, Kaiqiang Sun, Yanda Zhang, Yang-Xi Hu, Bowen Hu, Jian Zhao, Zhiqing He, Ru Ding, Weizhong Wang, Chun Liang · 2021 · Frontiers in Pharmacology
Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes
Pasquale Mone, Angela Lombardi, Urna Kansakar, Fahimeh Varzideh, Stanislovas S. Jankauskas, Antonella Pansini, Stefania Marzocco, Stefano De Gennaro, Michele Famiglietti, Gaetano Macina et al. · 2022 · Journal of Pharmacology and Experimental Therapeutics
Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy
Rosalinda Madonna, Stefania Moscato, Maria Concetta Cufaro, Damiana Pieragostino, Letizia Mattii, Piero Del Boccio, Sandra Ghelardoni, Riccardo Zucchi, Raffaele De Caterina · 2023 · Cardiovascular Research
Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, Tae Won Yi, SAMANTHA L. HOCKING, Jessica Dawson, Smriti Raichand, Andrzej S. Januszewski, Meg Jardine · 2024 · Nature Reviews Nephrology
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
Paola Fioretto, Andrea Giaccari, Giorgio Sesti · 2015 · Cardiovascular Diabetology
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Elisa Benetti, Raffaella Mastrocola, Giovanna Vitarelli, Juan Carlos Cutrìn, Debora Nigro, Fausto Chiazza, Eric Mayoux, Massimo Collino, Roberto Fantozzi · 2016 · Journal of Pharmacology and Experimental Therapeutics
Treatment of type 2 diabetes mellitus in the elderly
Funda Datlı Yakaryılmaz, Zeynel Abidin Öztürk · 2017 · World Journal of Diabetes
The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
Hongliang Li, Sung Eun Shin, Mi Seon Seo, Jin Ryeol An, Il‐Whan Choi, Won‐Kyo Jung, Amy L. Firth, Dae-Sung Lee, Mi‐Jin Yim, Grace Choi et al. · 2018 · Life Sciences
SGLT‐2 inhibitors and the risk of lower‐limb amputation: Is this a class effect?
Charles Khouri, Jean‐Luc Cracowski, Matthieu Roustit · 2018 · Diabetes Obesity and Metabolism
Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis
Xiaofang Yu, Saifei Zhang, Long Zhang · 2018 · International Journal of Endocrinology
SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)–Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice
Rebeca Ortega, Aida Collado, Francisca Selles, Herminia González Navarro, María‐Jesús Sanz, José Tomás Real, Laura Piqueras · 2019 · Arteriosclerosis Thrombosis and Vascular Biology
Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis
Martin Whyte, William Hinton, Andrew Peter McGovern, Jeremy N van Vlymen, Filipa Matos Ferreira, Silvio Calderara, Julie Mount, Neil M. Munro, Simon de Lusignan · 2019 · PLoS Medicine
Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA 1c Levels
Elvira D’Andrea, Deborah J. Wexler, Seoyoung C. Kim, Julie M. Paik, Ethan M. Alt, Elisabetta Patorno · 2023 · JAMA Internal Medicine
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus
Jordan, Jens, Tank, Jens, Heusser, Karsten, Heise, Tim, Wanner, Christoph, Heer, Martina, Macha, Sreeraj, Mattheus, Michaela, Lund, Søren S., Woerle, Hans J. et al. · 2017 · Journal of the American Society of Hypertension
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, Rita R. · 2021 · New England Journal of Medicine
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
Seon‐Ah Cha, Yong‐Moon Park, Jae‐Seung Yun, Tae‐Seok Lim, Ki‐Ho Song, Ki‐Dong Yoo, Yu‐Bae Ahn, Seung‐Hyun Ko · 2017 · Lipids in Health and Disease
Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes
Julie A. Lovshin, Harindra Rajasekeran, Yulyia Lytvyn, Leif Erik Lovblom, Shajiha Khan, Robel Z. Alemu, Amy Locke, VESTA S. LAI, Huaibing He, Lucinda R. Hittle et al. · 2017 · Diabetes Care
Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review
Keith C. Norris, Karen E. Smoyer, Catherine Rolland, Jan Van der Vaart, ElizaBeth Grubb · 2018 · BMC Nephrology
Do sodium‐glucose co‐transporter‐2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis
Milton Packer · 2018 · Diabetes Obesity and Metabolism
Diabetes pharmacotherapy and effects on the musculoskeletal system
Evangelia Kalaitzoglou, John L. Fowlkes, Iuliana Ristea Popescu, Kathryn M. Thrailkill · 2018 · Diabetes/Metabolism Research and Reviews
Hypoxia‐inducible factor 1‐alpha (HIF‐1α) as a factor mediating the relationship between obesity and heart failure with preserved ejection fraction
Ian Warbrick, Simon W. Rabkin · 2019 · Obesity Reviews
Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
Oriol Iborra Egea, Evelyn Santiago‐Vacas, Salva R. Yurista, Josep Lupón, Milton Packer, Stephane R B Heymans, Faiez M. Zannad, Javed Butler, Domingo Andrés Pascual-Figal, Antonio Lax et al. · 2019 · JACC Basic to Translational Science
The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
Hung-Yi Chen, Jing‐Yang Huang, Wun-Zhih Siao, Gwo‐Ping Jong · 2020 · Cardiovascular Diabetology
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Yi‐Chou Hou, Cai‐Mei Zheng, Tzung‐Hai Yen, Kuo‐Cheng Lu · 2020 · International Journal of Molecular Sciences
Post-Transplant Cardiovascular Disease
Kelly A. Birdwell, Meyeon Park · 2021 · Clinical Journal of the American Society of Nephrology
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
Antonio Ceriello, Doina Catrinoiu, Chanchal Chandramouli, Francesco Cosentino, Annique C. Dombrowsky, Baruch Itzhak, Nebojsa M. Lalic, Francesco Prattichizzo, Oliver Schnell, Petar M Seferovic et al. · 2021 · Cardiovascular Diabetology
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
Elke Roeb, Ali E. Canbay, Frank Tacke, Heike Bantel, Jörg Bojunga, Jan de Laffolie, Münevver Demir, Ulrike Walburga Denzer, A Geier, Wolf Peter Hofmann et al. · 2022 · Zeitschrift für Gastroenterologie
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes: Insights From the EXSCEL Trial
Fudim, Marat, White, Jennifer, Pagidipati, Neha J., Lokhnygina, Yuliya, Wainstein, Julio, Murin, Jan, Iqbal, Nayyar, Öhman, Peter, Lopes, Renato D., Reicher, Barry et al. · 2019 · Circulation
Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018
James J. Chamberlain, Eric L. Johnson, Sandra Leal, Andrew S. Rhinehart, Jay H. Shubrook, Lacie Peterson · 2018 · Annals of Internal Medicine
Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus
AG Unnikrishnan, Sanjay Kalra, Vedavati Bharat Purandare, Hardik Vasnawala · 2018 · Indian Journal of Endocrinology and Metabolism
Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito · 2019 · Journal of the American Heart Association
Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice
Mei Xue, Ting Li, Yue Wang, Yunpeng Chang, Ying Cheng, Yunhong Lu, Xiangyang Liu, Linxin Xu, Xiaoyu Li, Xiaochen Yu et al. · 2019 · Clinical Science
Therapeutic Manipulation of Myocardial Metabolism
Henri Honka, Carolina Solis‐Herrera, Curtis L. Triplitt, Luke Norton, Javed Butler, Ralph A. DeFronzo · 2021 · Journal of the American College of Cardiology
SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials
Alex Jia Yang Cheong, Yao Neng Teo, Yao Hao Teo, Nicholas L. X. Syn, How Ting Ong, Adriel Z. H. Ting, Alys Z. Q. Chia, Elliot Yeung Chong, Mark Y. Chan, Chi‐Hang Lee et al. · 2021 · Obesity
Mitochondrial Dysfunction in Cardiovascular Diseases: Potential Targets for Treatment
Jiaqi Yang, Qianyun Guo, Xunxun Feng, Yang Liu, Yujie Zhou · 2022 · Frontiers in Cell and Developmental Biology
Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis
Hallow, K. Melissa, Gebremichael, Yeshitila, Helmlinger, Gabriel, Vallon, Volker · 2017 · American Journal of Physiology-Renal Physiology
MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
RUSSELL L. ESTERLINE, Allan Arthur Vaag, Jan Oscarsson, Jiten P Vora · 2018 · European Journal of Endocrinology
Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
Guntram Schernthaner, Marie Helene Schernthaner-Reiter · 2018 · Diabetologia
Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes
Ferdinando Carlo Sasso, Luca Rinaldi, Nadia Lascar, Aldo Marrone, Pia Clara Pafundi, Luigi Elio Adinolfi, Raffaele Marfella · 2018 · Journal of Diabetes Research
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease
Cecilia C. Low Wang, Juuso Blomster, Gretchen Heizer, Jeffrey S. Berger, Iris Baumgärtner, F. Gerry R. Fowkes, Peter Held, Brian G. Katona, Lars Norgren, W. Schuyler Jones et al. · 2018 · Journal of the American College of Cardiology
Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts
Laween Uthman, Rianne Nederlof, Otto Eerbeek · 2019 · Cardiovascular Research
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
Björn Pasternak, Peter Ueda, Björn Eliasson, Ann‐Marie Svensson, Stefan Franzén, Soffia Guðbjörnsdóttir, Kristian Hveem, Christian Jonasson, Viktor Wintzell, Mads Melbye et al. · 2019 · BMJ